You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMasoprocol
Accession NumberDB00179  (APRD01084)
TypeSmall Molecule
GroupsApproved
DescriptionA potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Structure
Thumb
Synonyms
CHX 100
CHX-100
erythro-nordihydroguaiaretic acid
Masoprocolum
meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
meso-NDGA
meso-nordihydroguaiaretic acid
meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ActinexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7BO8G1BYQU
CAS number27686-84-6
WeightAverage: 302.3649
Monoisotopic: 302.151809192
Chemical FormulaC18H22O4
InChI KeyHCZKYJDFEPMADG-TXEJJXNPSA-N
InChI
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
IUPAC Name
4-[(2S,3R)-3-[(3,4-dihydroxyphenyl)methyl]-2-methylbutyl]benzene-1,2-diol
SMILES
C[C@@H](CC1=CC(O)=C(O)C=C1)[[email protected]](C)CC1=CC(O)=C(O)C=C1
Pharmacology
IndicationUsed for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).
Structured Indications Not Available
PharmacodynamicsMasoprocol is a novel antineoplastic agent. It is not known exactly how masoprocol works. Laboratory experiments have shown that masoprocol prevents cells similar to the ones found in actinic keratoses from multiplying. Masoprocol was withdrawn from the U.S. market in June 1996.
Mechanism of actionAlthough the exact mechanism of action is not known, studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known.
TargetKindPharmacological actionActionsOrganismUniProt ID
Arachidonate 5-lipoxygenaseProteinyes
inhibitor
HumanP09917 details
Related Articles
AbsorptionLess than 1%-2% is absorbed through the skin over a 4-day period following application.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 5-androstenedione.Experimental, Illicit
AbciximabMasoprocol may increase the anticoagulant activities of Abciximab.Approved
AcebutololMasoprocol may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aceclofenac.Approved
AcenocoumarolMasoprocol may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Acetovanillone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMasoprocol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Adapalene.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alendronic acid.Approved
AliskirenMasoprocol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMasoprocol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Masoprocol.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Amcinonide.Approved
AmikacinMasoprocol may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMasoprocol may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinMasoprocol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMasoprocol may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Masoprocol is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Anisodamine.Investigational
annamycinMasoprocol may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Antipyrine.Approved
Antithrombin III humanMasoprocol may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Masoprocol.Investigational
Aop200704Masoprocol may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanMasoprocol may increase the anticoagulant activities of Apixaban.Approved
ApramycinMasoprocol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Masoprocol is combined with Apremilast.Approved, Investigational
ArbekacinMasoprocol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMasoprocol may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMasoprocol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMasoprocol may decrease the antihypertensive activities of Arotinolol.Approved
AtenololMasoprocol may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Masoprocol.Approved
BalsalazideMasoprocol may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminMasoprocol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMasoprocol may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Masoprocol.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Masoprocol.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Masoprocol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Betamethasone.Approved, Vet Approved
BetaxololMasoprocol may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
BevantololMasoprocol may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Masoprocol.Approved, Investigational
BisoprololMasoprocol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMasoprocol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMasoprocol may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bucillamine.Investigational
BucindololMasoprocol may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Budesonide.Approved
BufuralolMasoprocol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMasoprocol may decrease the diuretic activities of Bumetanide.Approved
BupranololMasoprocol may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masoprocol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Masoprocol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Masoprocol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Masoprocol.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Masoprocol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMasoprocol may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMasoprocol may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Celecoxib.Approved, Investigational
CeliprololMasoprocol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMasoprocol may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Masoprocol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Masoprocol.Approved
CinoxacinMasoprocol may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMasoprocol may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidMasoprocol may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Masoprocol.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Masoprocol is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
CyclosporineMasoprocol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Masoprocol is combined with D-Limonene.Investigational
Dabigatran etexilateMasoprocol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMasoprocol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMasoprocol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinMasoprocol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Masoprocol is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Masoprocol is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinMasoprocol may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Masoprocol.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Masoprocol.Approved
DextranMasoprocol may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Masoprocol may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Masoprocol may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Masoprocol may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Masoprocol.Approved, Vet Approved
DicoumarolMasoprocol may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Masoprocol.Approved
DihydrostreptomycinMasoprocol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Masoprocol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Masoprocol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Masoprocol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masoprocol.Approved, Investigational
DoxorubicinMasoprocol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMasoprocol may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Masoprocol is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ebselen.Investigational
Edetic AcidMasoprocol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMasoprocol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Masoprocol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Masoprocol.Approved
EnoxacinMasoprocol may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinMasoprocol may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Masoprocol is combined with Epirizole.Approved
EpirubicinMasoprocol may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMasoprocol may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Masoprocol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Masoprocol.Approved
EquileninThe risk or severity of adverse effects can be increased when Masoprocol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Equilin.Approved
EsmololMasoprocol may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone sulfate.Approved
Etacrynic acidMasoprocol may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Masoprocol.Approved, Investigational
Ethyl biscoumacetateMasoprocol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Masoprocol is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Masoprocol is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Masoprocol.Vet Approved
FleroxacinMasoprocol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Masoprocol.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fludrocortisone.Approved
FluindioneMasoprocol may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMasoprocol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Masoprocol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Masoprocol.Approved, Nutraceutical, Vet Approved
FondaparinuxMasoprocol may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMasoprocol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Masoprocol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Masoprocol.Approved
FramycetinMasoprocol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMasoprocol may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateMasoprocol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMasoprocol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMasoprocol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Masoprocol.Approved, Withdrawn
GemifloxacinMasoprocol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMasoprocol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMasoprocol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMasoprocol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinMasoprocol may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Masoprocol is combined with HE3286.Investigational
HeparinMasoprocol may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Higenamine.Investigational
HirulogMasoprocol may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Masoprocol is combined with HMPL-004.Investigational
HydralazineMasoprocol may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Masoprocol.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Masoprocol.Approved
Hygromycin BMasoprocol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Masoprocol is combined with Icatibant.Approved
IdarubicinMasoprocol may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxMasoprocol may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Masoprocol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Masoprocol.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Masoprocol.Approved
IndenololMasoprocol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indoprofen.Withdrawn
INNO-206Masoprocol may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Masoprocol.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Masoprocol is combined with Istaroxime.Investigational
KanamycinMasoprocol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Masoprocol.Approved
LabetalolMasoprocol may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Masoprocol.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Leflunomide.Approved, Investigational
LepirudinMasoprocol may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMasoprocol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMasoprocol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Masoprocol.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Masoprocol.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Masoprocol.Approved
LomefloxacinMasoprocol may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Masoprocol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Masoprocol.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Masoprocol.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Magnesium salicylate.Approved
ME-609The risk or severity of adverse effects can be increased when Masoprocol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meloxicam.Approved, Vet Approved
MesalazineMasoprocol may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Masoprocol is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Masoprocol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Masoprocol.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMasoprocol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol.Approved
MetoprololMasoprocol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMasoprocol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Masoprocol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Masoprocol.Approved
MometasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Masoprocol.Approved
MoxifloxacinMasoprocol may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nabumetone.Approved
NadololMasoprocol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMasoprocol may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMasoprocol may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Naftifine.Approved
Nalidixic AcidMasoprocol may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Masoprocol is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Masoprocol is combined with NCX 4016.Investigational
NeamineMasoprocol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMasoprocol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMasoprocol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nepafenac.Approved
NetilmicinMasoprocol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nitroaspirin.Investigational
NorfloxacinMasoprocol may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMasoprocol may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Masoprocol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Olopatadine.Approved
OlsalazineMasoprocol may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Masoprocol.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Orgotein.Vet Approved
OtamixabanMasoprocol may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Masoprocol.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxaprozin.Approved
OxprenololMasoprocol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masoprocol.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Parecoxib.Approved
ParomomycinMasoprocol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinMasoprocol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMasoprocol may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMasoprocol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMasoprocol may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Masoprocol.Approved
PhenindioneMasoprocol may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonMasoprocol may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pimecrolimus.Approved, Investigational
PindololMasoprocol may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinMasoprocol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMasoprocol may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Piroxicam.Approved, Investigational
PlicamycinMasoprocol may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Masoprocol.Approved
PractololMasoprocol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Masoprocol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Masoprocol can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Propacetamol.Approved
PropranololMasoprocol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Masoprocol.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Masoprocol.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Masoprocol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Masoprocol.Vet Approved
Protein CMasoprocol may increase the anticoagulant activities of Protein C.Approved
Protein S humanMasoprocol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMasoprocol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMasoprocol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Masoprocol is combined with PTC299.Investigational
PuromycinMasoprocol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Masoprocol.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Masoprocol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Masoprocol.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Masoprocol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.Experimental, Investigational
ReviparinMasoprocol may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMasoprocol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Risedronate.Approved, Investigational
RivaroxabanMasoprocol may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinMasoprocol may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Masoprocol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Masoprocol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Masoprocol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Masoprocol is combined with Seratrodast.Approved, Investigational
SisomicinMasoprocol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolMasoprocol may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMasoprocol may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMasoprocol may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMasoprocol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Masoprocol.Approved
SpironolactoneMasoprocol may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Masoprocol is combined with SRT501.Investigational
StreptomycinMasoprocol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMasoprocol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineMasoprocol may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Sulindac.Approved
SulodexideMasoprocol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Masoprocol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Suprofen.Approved, Withdrawn
TacrolimusMasoprocol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Masoprocol.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Masoprocol.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Masoprocol.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Masoprocol.Approved, Investigational
TemafloxacinMasoprocol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Masoprocol.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiludronate.Approved, Vet Approved
TimololMasoprocol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tixocortol.Approved
TobramycinMasoprocol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolmetin.Approved
TorasemideMasoprocol may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Masoprocol.Approved
TranilastThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Masoprocol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Masoprocol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMasoprocol may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Masoprocol.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Trisalicylate-choline.Approved
TrovafloxacinMasoprocol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Masoprocol.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinMasoprocol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Masoprocol.Approved
WarfarinMasoprocol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMasoprocol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Masoprocol may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zileuton.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zomepirac.Withdrawn
ZorubicinMasoprocol may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL01XX10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (69 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier-0.5361
Caco-2 permeable+0.6215
P-glycoprotein substrateSubstrate0.6654
P-glycoprotein inhibitor INon-inhibitor0.9519
P-glycoprotein inhibitor IINon-inhibitor0.9144
Renal organic cation transporterNon-inhibitor0.886
CYP450 2C9 substrateNon-substrate0.7194
CYP450 2D6 substrateNon-substrate0.8261
CYP450 3A4 substrateNon-substrate0.5171
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8891
CYP450 2D6 inhibitorInhibitor0.8262
CYP450 2C19 inhibitorInhibitor0.8628
CYP450 3A4 inhibitorNon-inhibitor0.5833
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5322
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8614
BiodegradationNot ready biodegradable0.9632
Rat acute toxicity2.1491 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.6288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Univ arizona cancer center
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point185.5 °CPhysProp
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP3.44ALOGPS
logP4.76ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.21ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area80.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity86.62 m3·mol-1ChemAxon
Polarizability33.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-0901000000-c0d0caa2c363f17f6c94View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzylbutane lignans. These are lignan compounds containing a 2,3-dibenzylbutane moiety.
KingdomOrganic compounds
Super ClassLignans, neolignans and related compounds
ClassDibenzylbutane lignans
Sub ClassNot Available
Direct ParentDibenzylbutane lignans
Alternative Parents
Substituents
  • Dibenzylbutane lignan skeleton
  • Phenylpropane
  • 1,2-diphenol
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Audouin C, Mestdagh N, Lassoie MA, Houssin R, Henichart JP: N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase. Bioorg Med Chem Lett. 2001 Mar 26;11(6):845-8. [PubMed:11277534 ]
  2. Lambert JD, Meyers RO, Timmermann BN, Dorr RT: Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):85-90. [PubMed:11318430 ]
  3. Azadzoi KM, Heim VK, Tarcan T, Siroky MB: Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol Urodyn. 2004;23(3):258-64. [PubMed:15098224 ]
  4. West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita SP, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, West S, Williamson KS, Zemlan F, Hensley K: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004 Oct;91(1):133-43. [PubMed:15379894 ]
  5. Jeon SB, Ji KA, You HJ, Kim JH, Jou I, Joe EH: Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes. Biochem Biophys Res Commun. 2005 Mar 11;328(2):595-600. [PubMed:15694390 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23